These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 32223309)
21. Time to target uric acid to retard CKD progression. Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448 [TBL] [Abstract][Full Text] [Related]
22. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Wang S; Shu Z; Tao Q; Yu C; Zhan S; Li L Nephrology (Carlton); 2011 Nov; 16(8):767-76. PubMed ID: 21854506 [TBL] [Abstract][Full Text] [Related]
23. Hyperuricemia is associated with a lower glomerular filtration rate in pediatric sickle cell disease patients. Kaspar CDW; Beach I; Newlin J; Sisler I; Feig D; Smith W Pediatr Nephrol; 2020 May; 35(5):883-889. PubMed ID: 31960140 [TBL] [Abstract][Full Text] [Related]
24. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. Liu S; Perez-Ruiz F; Miner JN Joint Bone Spine; 2017 Mar; 84(2):183-188. PubMed ID: 27324603 [TBL] [Abstract][Full Text] [Related]
26. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. Kuriyama S Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883 [TBL] [Abstract][Full Text] [Related]
27. Uric acid and the development of hypertension. Hwu CM; Lin KH Med Sci Monit; 2010 Oct; 16(10):RA224-30. PubMed ID: 20885365 [TBL] [Abstract][Full Text] [Related]
28. The role of hyperuricemia and gout in kidney and cardiovascular disease. Edwards NL Cleve Clin J Med; 2008 Jul; 75 Suppl 5():S13-6. PubMed ID: 18822470 [TBL] [Abstract][Full Text] [Related]
30. Time to Target Uric Acid to Retard Chronic Kidney Disease Progression. Uchida S; Kumagai T; Chang WX; Tamura Y; Shibata S Contrib Nephrol; 2018; 192():56-68. PubMed ID: 29393121 [TBL] [Abstract][Full Text] [Related]
31. Uric Acid: The Lower the Better? Bellomo G; Selvi A Contrib Nephrol; 2018; 192():69-76. PubMed ID: 29393097 [TBL] [Abstract][Full Text] [Related]
32. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Nashar K; Fried LF Adv Chronic Kidney Dis; 2012 Nov; 19(6):386-91. PubMed ID: 23089273 [TBL] [Abstract][Full Text] [Related]
33. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial). Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427 [TBL] [Abstract][Full Text] [Related]
34. Mechanistic Insights of Soluble Uric Acid-related Kidney Disease. Pan J; Shi M; Ma L; Fu P Curr Med Chem; 2020; 27(30):5056-5066. PubMed ID: 30526453 [TBL] [Abstract][Full Text] [Related]
35. Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis. Marin M; Maalouf NM J Investig Med; 2018 Oct; 66(7):1031-1036. PubMed ID: 29622755 [TBL] [Abstract][Full Text] [Related]
36. Hyperuricemia and chronic kidney disease: an enigma yet to be solved. Dousdampanis P; Trigka K; Musso CG; Fourtounas C Ren Fail; 2014 Oct; 36(9):1351-9. PubMed ID: 25112538 [TBL] [Abstract][Full Text] [Related]
37. The relationships among hyperuricemia, body mass index and impaired renal function in type 2 diabetic patients. Li Y; Fan X; Li C; Zhi X; Peng L; Han H; Sun B Endocr J; 2018 Mar; 65(3):281-290. PubMed ID: 29237999 [TBL] [Abstract][Full Text] [Related]
38. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Bandukwala F; Huang M; Zaltzman JS; Nash MM; Prasad GV Am J Cardiol; 2009 Mar; 103(6):867-71. PubMed ID: 19268747 [TBL] [Abstract][Full Text] [Related]
39. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Tscharre M; Herman R; Rohla M; Hauser C; Farhan S; Freynhofer MK; Huber K; Weiss TW Atherosclerosis; 2018 Mar; 270():173-179. PubMed ID: 29432935 [TBL] [Abstract][Full Text] [Related]
40. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia. Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]